In addition to monitoring overall survival,
we assessed tumor burden, as measured by bioluminescence imaging, during the first 22 days of treatment (Figure 3).
Not exact matches
Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients
tumor mutational
burden to help inform and
assess immuno - oncology treatment.
Excitingly, a single dose of any of the three NK cell populations
assessed led to a significant reduction in
tumor burden, although the iPSC ‐ derived NK group demonstrating a trend toward overall better activity.